Clover Health (NASDAQ:CLOV) reported Q3 CY2025 revenue of $496.7 million, up 50.1% year on year, beating analyst estimates by 5.4%. However, its GAAP loss per share of $0.05 missed estimates by $0.02. Despite EBITDA guidance missing expectations, the company’s customer base grew to 109,226. Clover Health’s revenue has grown 23.3% annually over five years, but recent performance shows a pivot with revenue declining 2% in the last two years. Analysts project 31.9% revenue growth over the next 12 months. The stock dropped 17.5% to $2.90 after the results were announced.

Founded in 2014, Clover Health offers Medicare Advantage plans using technology for better patient care. The company’s operating margin is negative 14.8% over five years but has improved by 39.7% during this time. In Q3, operating margin was -4.9%. EPS has improved by 21.4% annually over five years, but Q3 EPS of -$0.05 missed estimates. Wall Street predicts full-year EPS to reach break even. Despite beating revenue expectations, Clover Health stock dropped 17.5% post-results. Analysts project 31.9% revenue growth in the next 12 months.

Read more at Stockstory.org – The Motley Fool: Clover Health’s (NASDAQ:CLOV) Q3 Sales Beat Estimates But Stock Drops 17.5%